IQ EQ FUND MANAGEMENT IRELAND Ltd Buys 19,575 Shares of Tempus AI, Inc. (NASDAQ:TEM)

IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its stake in shares of Tempus AI, Inc. (NASDAQ:TEM) by 429.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 24,133 shares of the company’s stock after buying an additional 19,575 shares during the quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in Tempus AI were worth $815,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. The Manufacturers Life Insurance Company boosted its holdings in shares of Tempus AI by 10.2% during the third quarter. The Manufacturers Life Insurance Company now owns 29,789 shares of the company’s stock worth $1,686,000 after acquiring an additional 2,765 shares during the period. Captrust Financial Advisors bought a new stake in Tempus AI in the 3rd quarter valued at $2,726,000. NEA Management Company LLC grew its holdings in Tempus AI by 17.8% in the 3rd quarter. NEA Management Company LLC now owns 5,385,979 shares of the company’s stock valued at $304,846,000 after buying an additional 813,169 shares in the last quarter. Benjamin Edwards Inc. bought a new position in Tempus AI during the 3rd quarter worth $725,000. Finally, Stifel Financial Corp acquired a new stake in shares of Tempus AI during the third quarter worth $218,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Trading Down 2.4 %

Tempus AI stock opened at $51.97 on Friday. The stock has a fifty day moving average of $58.13 and a 200-day moving average of $51.48. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Tempus AI, Inc. has a 52 week low of $22.89 and a 52 week high of $91.45.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Morgan Stanley raised their price target on shares of Tempus AI from $50.00 to $60.00 and gave the stock an “overweight” rating in a research report on Thursday, March 6th. Wolfe Research cut shares of Tempus AI from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 26th. William Blair reissued a “market perform” rating on shares of Tempus AI in a research report on Tuesday, February 25th. JPMorgan Chase & Co. lowered Tempus AI from an “overweight” rating to a “neutral” rating and raised their price objective for the stock from $50.00 to $55.00 in a research note on Tuesday, February 25th. Finally, Piper Sandler cut their target price on Tempus AI from $70.00 to $55.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Six research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $61.18.

Insiders Place Their Bets

In other Tempus AI news, COO Ryan Fukushima sold 20,000 shares of the company’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $39.61, for a total value of $792,200.00. Following the completion of the transaction, the chief operating officer now owns 982,442 shares of the company’s stock, valued at $38,914,527.62. This represents a 2.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Bradley A. Keywell sold 265,000 shares of Tempus AI stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $35.10, for a total value of $9,301,500.00. Following the sale, the insider now directly owns 15,218,365 shares in the company, valued at $534,164,611.50. The trade was a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 5,598,969 shares of company stock valued at $317,194,162.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.